Xencor Inc (XNCR)
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Xencor, Inc.
NASDAQ:XNCRHealthcare · Biotechnology
+2.09%$29.82
AH$30.10+0.94%vs close
Mkt Cap$2.22B
Float72.26M
O/S74.35M
Vol
$ Vol
RVOL
Inst Own-
SI17.0%
Earnings
Dilution
Financials Summary
Revenue$125.58M
Net Income-$91.92M
Total Assets$875.5M
Free Cash Flow-$138.27M
Debt & Equity
Debt 23%
Equity 77%
Total Debt$187.75M
Total Equity$635.59M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in XNCR's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$875.5M
Liabilities$239.91M
Accounts Receivable$29.3M
Accounts Payable$10.83M
Inventory$0
PP&E (Net)$90.9M
Goodwill$0
Intangible Assets$8.38M
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 |
| Revenue | $125.58M | $110.49M | $174.62M | $164.58M | $275.11M | $122.69M | $156.7M | $40.6M | $35.71M | $87.52M | $27.76M | $9.52M | $10.17M | $9.52M | $6.85M |
| YoY Growth | 13.7% | -36.7% | 6.1% | -40.2% | 124.2% | -21.7% | 285.9% | 13.7% | -59.2% | 215.3% | 191.6% | -6.4% | 6.8% | 39.1% | - |
| Cost of Revenue | $10.51M | $227.69M | $0 | $199.56M | $192.51M | $169.8M | $118.59M | $97.5M | $71.77M | $51.87M | $34.14M | $18.52M | $17M | $12.67M | $0 |
| Gross Profit | $115.06M | -$117.19M | $174.62M | -$34.98M | $82.6M | -$47.11M | $38.11M | -$56.9M | -$36.06M | $35.65M | -$6.38M | -$9M | -$6.83M | -$3.14M | $6.85M |
| Gross Margin | 91.6% | -106.1% | 100.0% | -21.3% | 30.0% | -38.4% | 24.3% | -140.1% | -101.0% | 40.7% | -23.0% | -94.5% | -67.1% | -33.0% | 100.0% |
| Research and Development | $239.43M | $227.69M | $253.6M | $199.56M | $192.51M | $169.8M | $118.59M | $97.5M | $71.77M | $51.87M | $34.14M | $18.52M | $17M | $12.67M | $12.66M |
| Selling, General, and Administrative | $63.64M | $58.89M | $53.38M | $47.49M | $38.84M | $29.69M | $24.29M | $22.47M | $17.5M | $13.11M | $11.96M | $7.46M | $3.69M | $3.09M | $3.64M |
| Other | -$10.51M | -$225.36M | $0 | -$199.56M | -$192.51M | -$169.8M | -$118.59M | $8.96M | $4.17M | $2.08M | $746K | $44K | $31K | $86K | $65K |
| Total Operating Expenses | $292.57M | $61.22M | $306.98M | $47.49M | $38.84M | $29.69M | $24.29M | $119.97M | $89.27M | $64.98M | $46.1M | $25.98M | $20.69M | $15.75M | $16.3M |
| Operating Income (EBIT) | -$177.5M | -$178.41M | -$132.36M | -$82.47M | $43.77M | -$76.8M | $13.82M | -$79.37M | -$53.56M | $22.54M | -$18.34M | -$16.46M | -$10.52M | -$6.23M | -$9.45M |
| Operating Margin | -141.4% | -161.5% | -75.8% | -50.1% | 15.9% | -62.6% | 8.8% | -195.5% | -150.0% | 25.8% | -66.1% | -172.9% | -103.4% | -65.4% | -138.0% |
| Interest Expense | $31.93M | $36.64M | $0 | $0 | $13K | $0 | $0 | $16K | $13K | $21K | $13K | $9K | $1.21M | $2.46M | $1.85M |
| Interest Income | $27.52M | $31.93M | $18.63M | $4.82M | $862K | $7.26M | $13.62M | $9.1M | $4.19M | $2.09M | $744K | $33K | $14K | $11K | $34K |
| Other Income (Expense) | $87.87M | -$56.52M | $12.73M | $27.96M | $38.86M | $7.46M | $13.36M | $8.96M | $4.17M | $2.08M | $746K | $35K | -$49.74M | -$2.36M | -$1.75M |
| Income Before Tax (EBT) | -$89.42M | -$234.92M | -$119.63M | -$54.51M | $82.63M | -$69.33M | $27.19M | -$70.41M | -$49.39M | $24.62M | -$17.59M | -$16.42M | -$60.26M | -$8.59M | -$11.2M |
| Income Tax Expense | $2.5M | $1.62M | $13.66M | $673K | $0 | $0 | $312K | $0 | -$463K | $991K | $0 | $0 | $533K | $0 | $0 |
| Net Income | -$91.92M | -$232.62M | -$133.13M | -$55.18M | $82.63M | -$69.33M | $26.88M | -$70.41M | -$48.92M | $23.63M | -$17.59M | -$16.42M | -$60.26M | -$8.59M | -$11.2M |
| Net Income Margin | -73.2% | -210.5% | -76.2% | -33.5% | 30.0% | -56.5% | 17.2% | -173.4% | -137.0% | 27.0% | -63.4% | -172.5% | -592.4% | -90.2% | -163.6% |
| Supplementary Data | |||||||||||||||
| EPS | -1.24 | -3.58 | -2.08 | -0.93 | 1.42 | -1.11 | 0.48 | -1.31 | -1.05 | 0.57 | -0.45 | -0.52 | -1.92 | -0.51 | -0.67 |
| Diluted EPS | -1.24 | -3.58 | -2.08 | -0.93 | 1.37 | -1.11 | 0.46 | -1.31 | -1.05 | 0.56 | -0.45 | -0.52 | -1.92 | -0.51 | -0.67 |
| Weighted Average OS | 74.24M | 65.04M | 60.50M | 59.65M | 58.38M | 57.21M | 56.53M | 53.75M | 46.82M | 41.27M | 39.02M | 31.39M | 31.35M | 16.69M | 16.69M |
| EBITDA | -$46.98M | -$186.17M | -$101.96M | -$45.7M | $90.14M | -$71M | $18.12M | -$75.88M | -$40.7M | $45.86M | -$16.47M | -$15.53M | -$58.34M | -$5.61M | -$8.75M |
| EBITDA Margin | -37.4% | -168.5% | -58.4% | -27.8% | 32.8% | -57.9% | 11.6% | -186.9% | -114.0% | 52.4% | -59.3% | -163.1% | -573.5% | -58.9% | -127.7% |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 |
| Assets | |||||||||||||||
| Current Assets | |||||||||||||||
| Cash and Cash Equivalents | $54.07M | $40.88M | $53.79M | $53.94M | $143.48M | $163.54M | $50.31M | $26.25M | $16.53M | $14.53M | $12.59M | $54.65M | $77.97M | $2.31M | $14.54M |
| Short-Term Investments | $493.66M | $456.9M | $539.93M | $569.12M | $190.63M | $439.46M | $476.77M | $268.12M | $207.6M | $115.61M | $83.84M | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $547.73M | $497.77M | $593.73M | $623.06M | $334.11M | $603M | $527.08M | $294.36M | $224.13M | $130.14M | $96.43M | $54.65M | $77.97M | $2.31M | $14.54M |
| Accounts Receivable | $29.3M | $60.85M | $11.29M | $29M | $66.38M | $23.94M | $24.78M | $10.19M | $1.14M | $8.62M | $44K | $2.97M | $59K | $354K | $29K |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$44K | -$2.97M | -$59K | $0 | $0 |
| Other Current Assets | $22.79M | $18.98M | $18.14M | $23.28M | $0 | $0 | $6.55M | $804K | $5.61M | $2.9M | $0 | $0 | $0 | $173K | $0 |
| Total Current Assets | $599.82M | $577.6M | $623.16M | $675.34M | $424.37M | $637.67M | $558.4M | $315.73M | $230.88M | $141.65M | $97.67M | $57.75M | $78.09M | $2.84M | $14.65M |
| Long-Term Assets | |||||||||||||||
| Property, Plant & Equipment Net | $90.9M | $98.14M | $100.12M | $93.6M | $59.97M | $32.28M | $25.18M | $11.81M | $7.09M | $3.1M | $2.31M | $899K | $307K | $283K | $384K |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $8.38M | $18.48M | $18.66M | $18.5M | $16.49M | $15.98M | $14.42M | $11.97M | $11.15M | $10.36M | $9.97M | $9.12M | $8.81M | $8.46M | $7.25M |
| Long-Term Investments | $175.89M | $256.83M | $209.72M | $58.21M | $331.73M | $17.1M | $71.53M | $236.11M | $139.2M | $273.34M | $96.89M | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $5M | $0 | $0 | $804K | $1.52M | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $498K | $885K | $1.03M | $613K | $653K | $212K | $713K | $311K | $265K | $103K | $63K | $59K | $100K | $77K | $93K |
| Total Long-Term Assets | $275.67M | $374.34M | $329.53M | $170.92M | $413.84M | $65.57M | $111.84M | $261M | $159.22M | $286.91M | $109.23M | $10.07M | $9.22M | $8.82M | $7.73M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $875.5M | $951.95M | $952.69M | $846.27M | $838.21M | $703.24M | $670.25M | $576.73M | $390.1M | $428.56M | $206.91M | $67.82M | $87.31M | $11.66M | $22.37M |
| Liabilities | |||||||||||||||
| Current Liabilities | |||||||||||||||
| Accounts Payable | $10.83M | $16.76M | $13.91M | $10.09M | $14M | $8.95M | $10.19M | $3.8M | $6.87M | $3.88M | $6.4M | $1.69M | $2.63M | $1.31M | $1.83M |
| Short-Term Debt | $43.27M | $48.45M | $6.33M | $0 | $0 | $0 | $2.17M | $0 | $0 | $0 | $0 | $0 | $0 | $20.92M | $18.46M |
| Current Income Tax Payable | $3.59M | $9.99M | $5.78M | $0 | $0 | $0 | $0 | $0 | $157K | $65K | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $31.68M | $30.32M | $37.29M | $92.61M | $45.2M | $40.08M | $88.81M | $95.52M | $33.29M | $2.25M | $3.44M | $1.95M | $5.06M |
| Other Current Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $8.99M | $315K | $60.3M | $193K | $108K | $0 | $0 | $0 | $0 |
| Total Current Liabilities | $95.91M | $87.43M | $84.71M | $63.84M | $70.74M | $121.06M | $66.56M | $53.85M | $101.34M | $106.29M | $43.43M | $6.2M | $7.48M | $25.48M | $26.2M |
| Long-Term Liabilities | |||||||||||||||
| Long-Term Debt | $76.48M | $115.16M | $14.64M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $125.18M | $0 | $0 | $0 | $1.93M | $1.2M | $5.62M | $7.93M | $542K | $2.34M | $6.3M | $5.67M | $7.11M |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$2K | -$10K | $0 |
| Other Long-Term Liabilities | $2.78M | $9.99M | $0 | $0 | $0 | $0 | $0 | $1.2M | -$4.54M | $397K | $507K | $0 | $0 | $0 | $0 |
| Total Long-Term Liabilities | $144M | $190.49M | $198.85M | $54.93M | $33.97M | $9.74M | $10.49M | $1.2M | $6.71M | $8.32M | $1.05M | $2.34M | $6.3M | $5.68M | $7.11M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $239.91M | $277.92M | $283.56M | $118.77M | $104.71M | $130.8M | $77.05M | $55.05M | $108.06M | $114.61M | $44.48M | $8.53M | $13.78M | $31.16M | $33.31M |
| Stockholders' Equity | |||||||||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $146.77M | $146.77M |
| Common Stock | $718K | $703K | $611K | $601K | $595K | $580K | $569K | $563K | $470K | $466K | $405K | $314K | $314K | $1K | $1K |
| Retained Earnings | -$795.96M | -$704.04M | -$464.37M | -$338.29M | -$283.1M | -$365.74M | -$296.4M | -$323.28M | -$287.29M | -$237.96M | -$261.58M | -$243.99M | -$227.57M | -$167.31M | -$158.72M |
| Comprehensive Income & Other | $1.58M | -$663K | $1.29M | -$6.95M | -$1.51M | $74K | $1.16M | -$971K | -$1.81M | -$1.44M | -$516K | -$6.55M | -$6.38M | -$6.28M | -$7.4M |
| Other Stockholders' Equity | $1.43B | $1.38B | $1.13B | $1.07B | $1.02B | $937.6M | $889.03M | $844.39M | $568.86M | $551.45M | $423.61M | $302.97M | $300.79M | $147.81M | $147.78M |
| Total Equity | $635.59M | $677.61M | $668.8M | $727.5M | $733.5M | $572.44M | $593.2M | $521.68M | $282.05M | $313.95M | $162.43M | $59.29M | $73.53M | -$19.5M | -$10.94M |
| Minority Interest | $0 | -$3.58M | $337K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $875.5M | $955.53M | $952.36M | $846.27M | $838.21M | $703.24M | $670.25M | $576.73M | $390.1M | $428.56M | $206.91M | $67.82M | $87.31M | $11.66M | $22.37M |
| Supplementary Data | |||||||||||||||
| Total Debt | $187.75M | $231.95M | $83.43M | $59.63M | $33.97M | $11.63M | $10.73M | $0 | $0 | $0 | $0 | $0 | $10K | $20.94M | $18.47M |
| Net Debt | $133.67M | $191.08M | $29.64M | $5.69M | -$109.51M | -$151.92M | -$39.58M | -$26.25M | -$16.53M | -$14.53M | -$12.59M | -$54.65M | -$77.97M | $18.63M | $3.94M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 |
| Operating Activities | |||||||||||||||
| Net Income | -$91.92M | -$236.54M | -$133.13M | -$55.18M | $82.63M | -$69.33M | $26.88M | -$70.41M | -$48.92M | $23.63M | -$17.59M | -$16.42M | -$60.26M | -$8.59M | -$11.2M |
| Depreciation & Amortization | $10.51M | $12.11M | $11.5M | $8.8M | $7.49M | $5.79M | $4.3M | $3.25M | $2.03M | $1.47M | $1.11M | $882K | $711K | $527K | $607K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | -$18.97M | $0 | $0 | $0 | $0 | $65K | $0 | $0 | $189K | $302K | $1.1M |
| Stock-Based Compensation | $43.23M | $53.28M | $0 | $48.91M | $36.98M | $31.62M | $31.85M | $20.55M | $13.65M | $7.85M | $4.87M | $1.86M | $198K | $29K | -$57K |
| Changes in Working Capital: | |||||||||||||||
| Accounts Receivable | $28.73M | -$32.67M | $19.83M | $36.86M | -$54.94M | -$185K | -$11M | -$9.04M | $7.47M | -$8.57M | $2.92M | -$2.91M | $293K | -$325K | -$29K |
| Inventory | $0 | $0 | $0 | $0 | $1.4M | $0 | $0 | -$1.36M | -$5.64M | $828K | -$541K | $786K | $224K | $370K | $130K |
| Accounts Payable | -$3.95M | $2.85M | $3.83M | -$3.91M | $5.05M | -$1.24M | $6.39M | -$3.07M | $2.99M | -$2.52M | $4.71M | -$943K | $1.32M | -$522K | -$239K |
| Other Working Capital | $22.67M | -$10.57M | -$4.53M | $15.92M | -$54.11M | $49.6M | $10.05M | -$19.69M | -$8.58M | $69.55M | $29.81M | -$5.12M | $2.1M | -$4.54M | $6.76M |
| Total Working Capital Change | $47.45M | -$40.4M | $19.13M | $48.87M | -$102.6M | $48.18M | $5.44M | -$33.17M | -$3.76M | $59.29M | $36.9M | -$8.18M | $3.94M | -$5.02M | $6.62M |
| Other Non-Cash Items | -$144.38M | $9.36M | $24.58M | -$26.91M | -$22.38M | -$21.26M | -$4.09M | $21K | $3.32M | $2.32M | $1.38M | $507K | $49.77M | $1.7M | $1.85M |
| Net Cash from Operating | -$135.12M | -$202.19M | -$77.93M | $24.48M | -$16.85M | -$5M | $64.37M | -$79.76M | -$33.68M | $94.62M | $26.67M | -$21.35M | -$5.45M | -$11.05M | -$1.08M |
| Investing Activities | |||||||||||||||
| Capital Expenditures | -$3.15M | -$6.1M | -$21.25M | -$38.49M | -$15.98M | -$10.54M | -$7.35M | -$9.15M | -$7.28M | -$3.01M | -$3.67M | -$2.29M | -$1.29M | -$1.26M | -$1.42M |
| Acquisitions | $0 | $0 | $501K | $0 | -$2.66M | $0 | $0 | -$1.93M | -$33.92M | $920K | -$1.75M | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$298.89M | -$595.05M | -$782.9M | -$387.93M | -$509.6M | -$643.66M | -$496.86M | -$377.84M | -$76.53M | -$316.15M | -$215.8M | $0 | $0 | $0 | $0 |
| Sales of Investments | $427.64M | $596.66M | $693.09M | $306.61M | $485.15M | $757.62M | $456.92M | $222.13M | $115.76M | $105.5M | $34.36M | $0 | $0 | $0 | $0 |
| Other Investing Activities | $14.39M | -$3.38M | $0 | $90K | -$3.16M | -$3.23M | -$3.69M | $2.02M | $33.92M | -$920K | $1.75M | $2K | $16K | $97K | $133K |
| Net Cash from Investing | $139.99M | -$7.87M | -$110.56M | -$119.72M | -$46.25M | $100.19M | -$50.97M | -$164.77M | $31.95M | -$213.65M | -$185.11M | -$2.28M | -$1.28M | -$1.16M | -$1.29M |
| Financing Activities | |||||||||||||||
| Debt Repaid | - | - | - | - | - | - | - | - | - | - | - | $8K | $10K | $12K | $11K |
| Common Stock Issuance | $9.96M | $201.26M | $5.39M | $0 | $28.92M | $0 | $0 | $260.25M | $3.73M | $126.55M | $122.91M | $0 | $80.52M | $0 | $0 |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$1.73M | -$4.1M | $183.33M | $5.7M | $14.12M | $18.04M | $10.66M | -$6M | $3.73M | -$5.57M | -$6.53M | $316K | -$8.11M | $0 | $0 |
| Net Cash from Financing | $8.23M | $197.15M | $188.72M | $5.7M | $43.04M | $18.04M | $10.66M | $254.24M | $3.73M | $120.97M | $116.38M | $308K | $82.39M | -$12K | -$11K |
| Forex Effect | $0 | $0 | -$380K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $13.1M | -$12.91M | -$152K | -$89.54M | -$20.06M | $113.23M | $24.07M | $9.72M | $2M | $1.94M | -$42.06M | -$23.33M | $75.66M | -$12.22M | -$2.38M |
| Supplementary Data | |||||||||||||||
| Operating Cash Flow | -$135.12M | -$202.19M | -$77.93M | $24.48M | -$16.85M | -$5M | $64.37M | -$79.76M | -$33.68M | $94.62M | $26.67M | -$21.35M | -$5.45M | -$11.05M | -$1.08M |
| Capital Expenditure | -$3.15M | -$6.1M | -$18.45M | -$43.4M | -$15.98M | -$13.77M | -$11.04M | -$9.15M | -$7.28M | -$3.01M | -$3.67M | -$2.29M | -$1.29M | -$1.26M | -$1.42M |
| Free Cash Flow | -$138.27M | -$208.28M | -$96.37M | -$18.92M | -$32.83M | -$18.77M | $53.34M | -$88.9M | -$40.96M | $91.61M | $22.99M | -$23.64M | -$6.75M | -$12.31M | -$2.5M |
| Cash at Beginning | $41.26M | $54.17M | $53.94M | $143.48M | $163.54M | $50.31M | $26.25M | $16.53M | $14.53M | $12.59M | $54.65M | $77.97M | $2.31M | $14.54M | $16.92M |
| Cash at End | $54.36M | $41.26M | $53.79M | $53.94M | $143.48M | $163.54M | $50.31M | $26.25M | $16.53M | $14.53M | $12.59M | $54.65M | $77.97M | $2.31M | $14.54M |